Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $15.67 (6.24% downside)

Current Analysts' Coverage Summary for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/4/2014ZacksUpgradeUnderperform -> Neutral$15.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00ViewTweet This Rating  Share This Rating on StockTwits
9/16/2014Brean CapitalBoost Price TargetBuy$18.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
8/21/2014Roth CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014MKM PartnersReiterated RatingNeutral$13.00ViewTweet This Rating  Share This Rating on StockTwits
5/15/2014Jefferies GroupReiterated RatingBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
11/26/2013Piper JaffrayInitiated CoverageOverweight$20.00ViewTweet This Rating  Share This Rating on StockTwits
9/30/2013JPMorgan Chase & Co.Lower Price TargetOverweight$15.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013Cowen and CompanyReiterated RatingBuy$17.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013William BlairReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
3/1/2013Deutsche BankLower Price TargetBuy$13.00 -> $12.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2013Lazard LtdInitiated CoverageBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/27/2012 forward)